New drug combination for relapsed T-cell blood cancer in teens and young adults
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of four drugs (venetoclax, dexamethasone, bortezomib, and daratumumab) to treat T-cell acute lymphoblastic leukemia or lymphoma that has come back or stopped responding to prior treatment. The goal is to see if this combination can help patients aged 12–30 achieve remission.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 12 and 30 years old and weigh at least 40 kg (about 88 pounds)
- You have been diagnosed with relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) or T-cell acute lymphoblastic lymphoma (TLBL)
- Your heart, liver, and kidney function meet minimum requirements based on recent blood tests and heart imaging
- You are willing to use effective birth control during and after the trial (4 months post-treatment for men; for women until menopause or surgical sterilization)
- You have adequate performance status—you can perform light activities and care for yourself (a score of at least 60 on standard scales)
- You have not received other anti-cancer treatment within 14 days (or 5 half-lives, whichever is shorter) before starting this trial
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (calaspargase, decitabine, and venetoclax) for children, teens, and young adults with T-cell leukemia or lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help destroy cancer cells.
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
This trial tests a combination of two oral drugs (venetoclax and decitabine/cedazuridine) for children and teens whose acute myeloid leukemia (AML) has returned or not improved after prior treatment. The goal is to find a safe dose and see if the drugs can help shrink or control the leukemia.
This trial tests a combination of chemotherapy drugs (hyper-CVAD) plus a targeted pill called venetoclax for children and young adults with a type of leukemia that has returned or not responded to treatment. The goal is to see if this combo can help control the leukemia.
This trial tests a combination of venetoclax with liposome chemotherapy (daunorubicin and cytarabine) for adults with acute myeloid leukemia (AML) that is back after treatment or not responding, and for some newly diagnosed cases. It aims to shrink leukemia and help more people achieve remission.
This trial tests a new drug combination (ziftomenib, venetoclax, and azacitidine) in children and young adults with acute leukemia that has come back or not responded to treatment. It may help if your child's leukemia has certain genetic changes (like KMT2A, NPM1, or NUP98).
Hear when a new T-cell Acute Lymphoblastic Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.